CERTIFICATE OF MAILING hapthise brespondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date. **Typed or Printed Name** Goldstein Signature 4ug US+ 24, 2001 BALA001CIP Attorney Docket INFORMATION **DISCLOSURE STATEMENT** Address to:

Commissioner for Patents Washington, D.C. 20231

	<u>1</u>
First Named Inventor	Naomi Balaban
Application Number	09/839,695
Confirmation No.	To Be Assigned
Filing Date	April 19, 2001
Group Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Title	Methods and Compositions for the Treatment and Prevention of Staphylococcus Aureus Infections

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-1449 listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

All of the references identified herein were disclosed in parent application Serial No. 09/054,331 and, as such, copies thereof are not included pursuant to the provisions of 37 C.F.R. §1.98(d).

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815 may be charged therefor.

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

BOZICEVIC. FIELD & FRANCIS LLP

200 Middlefield Road, Suite 200

Menlo Park, CA 94025 Telephone: (650) 327-3400 Facsimile: (650) 327-3231

F:\DOCUMENT\BALA\001cip\IDS.doc

By:

Carol L. Francis

Registration No. 36,

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION

Form PTO-1449 (Modified)

(Use several sheets if necessary)

ATTY. DO	OCKET	NO.
BAI	LA00:	LCIP

SERIAL NO. 09/839,695

APPLICANT

Naomi Balaban

FILING DATE

GROUP

April 19, 2001 To Be Assigned

U.S. PATENT DOCUMENTS

		a ir								
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date			
			FORE	EIGN PATENT DOCUMENTS	.1	<u> </u>	<u> </u>			
		Document Number	Date	Country	Class	Subclass	Trans	Translation		
	AA	WO96/10579	Apr 11, 1996	PCT			Yes	No		
	АВ	WO97/44349	Nov 27, 1997	PCT						
:			OTHER ART (Inclu	ding Author, Title, Date, Pertinent Po	ages, Etc.)					
	AC	Balaban et al., ", Acad. Sci. USA (llation of toxin synthesis b 9-1623	y Staphyloc	coccus aure	as" Proc.1	Vatl.		
	AD									
	AE									
	AF									
	AG	Ji, et al. "Bacterial Interference Caused by Autoinducing Peptide Variants" <i>Science</i> (1997) 276:2027-2030.								
	АН			vity Analysis of Synthetic nsible for Virulence," <i>Proc</i>						
	AI	Morfeldt et al., "Activation of alpha-toxin translation in <i>Staphylococcus aureus</i> by the trans- encoded antisense RNA, RNAIII" <i>EMBO Journal</i> (1995) 14(18):4469-4577								
	AJ	Novick, et al., "Synthesis of staphylococcal virulence factors is controlled by a regulatory RNA molecule" <i>EMBO Journal</i> (1993) 12(10):3967-3975								
***************************************	AK									
	AL		lethicillin-resis	tant <i>Staphylococcus aureu</i>	s in U.S. h	ospitals, 19	975-1991	' Infe		
	AM	Silverstein et al.	, "Host Defens	se against bacterial and fu ny, Philadelphia, B.D. Dav						

F:\DOCUMENT\BALA\001cip\IDS - PTO 1449.doc

EXAMINER DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.